Results 261 to 270 of about 496,062 (355)
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Arthritis &Rheumatology, EarlyView.Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective To evaluate the applicability of the 2016 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) macrophage activation syndrome (MAS) classification criteria in patients with Still disease and systemic juvenile idiopathic arthritis ...
Remco G. A. Erkens +14 more
wiley +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
Do Postnatal Corticosteroids Negatively Impact the Neurodevelopmental Outcomes of Extremely Preterm Infants? [PDF]
J Pediatr Pharmacol Thereuropepmc +1 more source
Therapeutic options for extramedullary involvement in multiple myeloma. [PDF]
Clin Exp MedZhao J, Cui Y, Fang B.
europepmc +1 more source
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
New England Journal of Medicine, 2007 Jaya Ghosh +6 more
semanticscholar +1 more source